RT Journal Article
SR Electronic
T1 Beyond the limitation of randomized controlled trials (RCTs)-current drug repositioning by using human induced pluripotent stem (iPS) cells technology-
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 111435
DO 10.1101/111435
A1 M.D. Midori Okabe
YR 2017
UL http://biorxiv.org/content/early/2017/02/24/111435.abstract
AB To ensure the clinical value of medical interventions, randomized controlled trials (RCTs) are necessary. However, the results of conventional RCTs cannot show individual therapeutic efficacy and safety for medical intervention to a targeted patient. It is the most important weak point of conventional RCTs. Here I show that the new clinical research method by using human induced pluripotent stem (iPS) cells technology will be able to complement the most important weak point of conventional RCTs.As the representative examples, I show the new clinical values of statins (inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase) found by using human iPS cells technology in achondroplasia or hanatophoric dysplasia (type 1) case and hepatitis C virus (HCV) infection case. Furthermore, they are also important examples for drug repositioning.Therefore, my article would be valuable as a scientific communication for physicians and/or scientists.